This was my interview with Dr. Alok Khorana of the Cleveland Clinic at the ASCO Annual Meeting on May 30, 2015. Earlier that day, there was a presentation demonstrating significant benefit using pembrolizumab in patients with microsatellite unstable (MSI) tumors.